相关实验视频

Updated: Jan 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在固体瘤中准TROP2:Datopotamab Deruxtecan的临床概况和作用

Rachel Lucky¹, Lauren Thornburg², Zachery Halford¹

¹Union University College of Pharmacy, Jackson, TN, USA.

The Annals of pharmacotherapy

|December 1, 2025

概括

达托帕马布德鲁克斯泰坎 (Dato-DXd) 是一种新的TROP2定向抗体-药物结合物,已批准用于高级固体瘤. 它在HR+/HER2-乳腺癌和EGFR突变NSCLC中显示出有效性,副作用可控.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
药物开发药物开发

背景情况:

热原体细胞表面抗原2 (TROP2) 是几种高级固体瘤的目标.
抗体与药物联合体 (ADCs) 是一个有前途的治疗方式.
达托帕马布德鲁克斯泰坎 (Dato-DXd) 是一种新型的TROP2指导的ADC.

研究的目的:

评估Dato-DXd的药理学,疗效,安全性和临床效用.
在患有晚期固体瘤的患者中评估Dato-DXd,特别关注乳腺癌和非小细胞肺癌 (NSCLC).

主要方法:

在PubMed和ClinicalTrials.gov (2010-2025) 的综合文献搜索.
包括来自临床试验,文章,指南,摘要和包装插件的数据.
专注于TROP2导向的ADC-datopotamab deruxtecan (Dato-DXd). 这是一个很好的方法.

主要成果:

达托-DXd在2025年获得FDA的加速批准,用于HR+/HER2-乳腺癌和EGFR突变NSCLC.
在乳腺癌中,Dato-DXd显示出更高的疗效 (36.4% RR) 与化疗 (22.9% RR) 相比.
在NSCLC中,Dato-DXd表现出显著的响应率 (26.4%-35.8%),与多塞 (12.8%) 相比.
副作用包括口炎,恶心,脱发和眼部事件;间歇性肺病/肺炎是一个关键的安全问题.

结论:

达托-DXd是先前治疗HR+/HER2-乳腺癌和EGFR突变NSCLC的可行的治疗选择.
针对TROP2的ADC为重度预治疗的患者提供了临床益处,具有可管理的安全性.
需要进行进一步的研究,以确定在不断变化的ADC环境中Dato-DXd的最佳测序和定位.

关键词:

抗体与药物结合物的结合物.乳腺癌乳腺癌乳腺癌数据可以被测试.德鲁克斯可以是德鲁克斯非小细胞肺癌的肺癌.

更多相关视频

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.